Source: Komo Plant Based Foods Inc.
  • Komo Plant Based Foods (YUM) is expanding its frozen meal line to all 9 SKUs in Fortinos stores across the Greater Toronto Area
  • Expanding their business with this brand under the banner of Loblaw makes their meals more accessible to families in Canada’s largest city
  • Fortinos is a supermarket chain with 23 stores across the Greater Toronto Area
  • Komo Plant Based Foods (YUM) was down 4.76 per cent, trading at $0.20 per share at 11:15 am ET

Komo Plant Based Foods (YUM) is expanding its frozen meal line to all nine SKUs in Fortinos stores across the Greater Toronto Area.

William White, CEO of Komo Plant Based Foods, said that expanding their business with this brand under the banner of Loblaw makes their meals more accessible to families in Canada’s largest city.

“We believe that our brand resonates with the people of Toronto, and we’re passionate about creating delicious and wholesome plant-based meals that fit the needs of busy households. We believe that our meals offer a healthy and convenient option for families who want to eat well without sacrificing taste, health or convenience.”

Fortinos is a supermarket chain with 23 stores across the Greater Toronto Area.

Komo’s nine plant-based products are sold directly to consumers through the company’s e-commerce website and a distribution network of online and brick-and-mortar grocery, convenience, and natural retailer channels.

All of the company’s products are 100-per-cent plant-based, made free from preservatives and have an 18-month frozen shelf life.

Komo Plant Based Foods (YUM) was down 4.76 per cent, trading at $0.20 per share at 11:15 am ET.


More From The Market Online

Unsung profits: Three money-making penny stocks trading for cheap

To make money in stocks, you need to develop a strong sense for the irrational, a quality often found among cheaply priced penny stocks.
stock market down

@ the Bell: TSX hits near-month high

The TSX rose near highs not seen in a month, but a split between indices capped gains as mining and energy were the only…

FSD Pharma submits MS treatment clinical trial for review in Australia

FSD Pharma (CSE:HUGE) submits its MS treatment's Phase-1 Multiple Ascending Doses Clinical Trial Application for ethics review in Australia.

Cloud DX signs fourth contract with a provincial health authority

Cloud DX (TSXV:CDX) signs its fourth contract with a provincial health authority for remote patient monitoring.